cover image for Quarterly Drug Pipeline: January 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-january-2026...

cover images for Quarterly Drug Pipeline: April 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2026 Prime...

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2025 Prime...

*Orphan drug status intravenous (IV); Prescription Drug User Fee Act (PDUFA) Cell therapy: Aims to replace or repair damaged cells through transplantation of healthy ones Editorial team Editor's...

Specialty Pharmacy Continuum

Prime study finds individuals enrolled in the program for six months who took GLP-1 drugs for obesity lost an average of 22.5 pounds, and 95% of patients remained on GLP-1 therapy

Managed Healthcare Executive